Illumina MiSeq i100Plus sequencing system
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The Food and Drug Administration is seeking to acquire Illumina MiSeq i100Plus sequencing systems to upgrade its genomic sequencing capabilities. These new desktop systems are intended to provide higher throughput, increased efficiency, and improved accuracy while reducing the overall cost per genome compared to previous models. The equipment will support OAMT scientists in the in-silico design and development of FDA sequencing applications for foodborne pathogens, including various bacteria, viruses, and parasites. The instruments will be used to optimize next generation sequencing laboratory protocols and evaluate Targeted Amplicon Sequencing against whole genome and metagenome sequencing methods. The procurement plan specifies the acquisition of three instruments in total, distributed among MOD1, CPK1, and the Moffett facility.
General Info
Place of Performance
USASet-Aside
Documents
0AI Contract Breakdown
Uniform Contract FormatNo documents to break down
The breakdown needs solicitation documents. None were found from this contract's source.
Organization & Contact Information
Full Description
Similar Contracts
Same NAICS industry code
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
